Advertisement

Topics

Novartis' Mayzent shows promise in boosting cognitive abilities in MS

06:03 EDT 10 May 2019 | SmartBrief

A late-stage study of Novartis' multiple sclerosis drug Mayzent showed patients' cognitive abilities improved versus placebo. -More

Original Article: Novartis' Mayzent shows promise in boosting cognitive abilities in MS

NEXT ARTICLE

More From BioPortfolio on "Novartis' Mayzent shows promise in boosting cognitive abilities in MS"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...